Jul 6, 2026 · 11 min · 10 segments
In this episode of Bench to Boardroom, we explore why the probability of success in biopharma extends far beyond the science itself. While the industry is built on evidence and innovation, investment…
Today's episode begins with what may sound like an uncomfortable observation.
For an industry built on evidence, statistics, and scientific rigor, biopharma doesn't always make decisions rationally.
This isn't meant as criticism.
It's an observation.
Compare our industry with aerospace, or semiconductor manufacturing, or automotive engineering.
Those industries routinely build probabilistic decision frameworks into nearly every major investment.
Projects advance because cumulative evidence improves the probability of technical and commercial success.
In life sciences, however, we occasionally see something different.
Scientific enthusiasm overrides commercial reality.
Capital follows fashionable modalities.
Programs continue long after probabilities have shifted against them.
Conversely, highly promising assets are sometimes abandoned because they fall outside prevailing investor narratives.
The result? Capital isn't always allocated where probability-adjusted value is highest.
And perhaps that's the industry's biggest opportunity.
Because the probability of success isn't one number.
It's an ecosystem.
Today I'd like to discuss what I believe that ecosystem looks like.
Today's episode begins with what may sound like an uncomfortable observation.
For an industry built on evidence, statistics, and scientific rigor, biopharma doesn't always make decisions rationally.
This isn't meant as criticism.
It's an observation.
Compare our industry with aerospace, or semiconductor manufacturing, or automotive engineering.
Those industries routinely build probabilistic decision frameworks into nearly every major investment.
Projects advance because cumulative evidence improves the probability of technical and commercial success.
In life sciences, however, we occasionally see something different.
Scientific enthusiasm overrides commercial reality.
Capital follows fashionable modalities.
Programs continue long after probabilities have shifted against them.
Conversely, highly promising assets are sometimes abandoned because they fall outside prevailing investor narratives.
The result? Capital isn't always allocated where probability-adjusted value is highest.
And perhaps that's the industry's biggest opportunity.
Because the probability of success isn't one number.
It's an ecosystem.
Today I'd like to discuss what I believe that ecosystem looks like.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.